Phase 2 randomized trial: immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet

Commentaries: China’s Ad5 vectored COVID-19 vaccine safe and induces immune response – News Medical AND CanSino COVID-19 vaccine generates immune response in 90% of patients – UPI

Related Commentary on Twitter

https://twitter.com/TheLancet/status/1285209554775617536